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Summary: Antiviral therapy of human immundeficiency virus (HIV) infection is currently based on Inhibition
of reverse transcriptase by dideoxynucleosides, such äs azidothymidine. Because of widespread toxicity it is
reasonable to selectively target these drugs to infected cells. This may be accomplished utilizing drug-LDL
conjugates, which are interüalized via cell specific receptor pathways. With respect to HIV infection, scavenger
receptors of the macrophage System seems to offer a hopefull perspective. This pathway requires chemical
modification of surface polarity of the LDL. Cell experiments were conducted in HepG2 hepatocytes, which
express apolipoprotein B receptors, and in P388 macrophages, which express scavenger receptors. LDL particles
to be conjugated were isolated from blood donor plasma and from LDL-apheresis waste material. Non-
covalent LDL conjugation with amphiphilic nucleoside derivatives produced only an unspecific nucleoside
transfer to cell membranes, due to instability of the LDL conjugates. An experimental method (coincubation
test) was developed to identify those conjugates that are stable in the presence of other lipophilic compartments.
Covalent coupling pf nuclepsides to the apolipoprotein B moiety of LDL particles resulted in stable conjugates.
As a consequence, the surfaee Charge became negative, and the LDL displayed scavenger receptor affmity
rather than apolipoprotein B receptor affinity. Selective targeting of nucleosides to macrophages can be
accomplished by covalent coupling to LDL.
Introduction . , - . - . . . , * · *u rit has been shown that ennchment via the apolipo-
The concept of drug targeting dätes back to the in- protein B receptor pathway is insigniflcant (8 — 10).
genious ideas Paul Ehrlich (1). Since the recpgtiitiön e<J ^ a,so an attractive
of receptor-mediated LDL^uptake m tumour oblb tion for the tieatamt of viral diseases. These diseases
(2^6), drug targeting of cytotox,c agents v,a LDL1) be treated effectiyd b antimetaboütes, such äs
has been envisiged äs a means of impröving the 3zidoth^dine (15 16)) which cause tennination of
chemotherapy of neoplastic diseases (7). Howeyer, DNA chain el tipn in the infected cell> and are
despite many efforts, no pracUcable regime of cell- therefore ̂  tQ curtaij ̂  m Qf myl HQW_
selective dehvery of a LDL-drug-conjugate has so far ^ tojd tQ ̂  h oetic and neura,
been developecL This is maanly due to the failure to , tem has hindered long.term high dose regimes with
obtam stable LDL-drug-conjugates (8, 9). Moreover^ j . " _ ' agents
') Abbreviations: LDL·, low densify üpoprotein; HIV, human Recently, it was found that the raononuclear-phago-
immunodefieiency virus. cytic cell System serves äs a virus reservoir m HIV
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infection (11 — 15). This cell family possesses scaven-
ger receptors, in contrast to the ubiquitous LDL apo-
lipoprotein B receptor that are found, e. g. on blood
monocytes, B and T lymphocytes and hepatocytes
(17, 18). Thus, utilization of the scavenger receptor
pathway may avoid drug delivery to sensitive albeit
non-infected cells. Drug delivery via this receptor has
not been previously suggested. Linkage of azido-
thymidine or antisense oligonucleotides to LDL, in a
way that favoured selective scavenger receptor uptake
by macrophages, would offer a new route for antiviral
chemotherapy.
The aim of our work was to obtain stable nucleoside/
LDL conjugates, which will be taken up selectively
by the scavenger receptor of macrophages. It was
intended to prepare stable nucleoside-LDL conjugates







cytidine were prepared äs described in 1. c. (l 9).
Electrophoresis
SDS-PAGE was performed according to the method of Cardin
et al. (22) modified äs previously described (23). Agarose lipo-
protein electrophoresis was conducted with the Paragon Lipo
Kit (Fa. Beckman).
Chemical ana lys i s
Total cholesterol was determined using the cholesteroloxidase/
4-aminophenazone method, Monotest (Boehringer Mannheim,
Germany); protein was determined according to Lowry et al.
(24).
Isolat ion of LDL particles
LDL was isolated from citrated plasma of blood donors (cour-
tesy Dr. Eckstein), and from membrane differential filtration
apheresis (20). LDL (fraction d = 1.019-1.063 kg/l) and li-
poprotein-deficient serum (d > 1.21 kg/l) were prepared by
sequential ultracentrifugation (21). LDL fractions were dialysed
36h against Standard buffer (0.15 mol/1 NaCl, 0.5 mmol/1
EDTA, pH 7.4, 4 °C). Defibrination of lipoprotein-deficient
serum was performed by incubation with thrombin (20 · l O3
NIH U/l) at 24 °C for 10 min, and centrifugation at 30000g
for 90 min. The purified fractions were sterile filtered over 0.22
Millex filter (Millipore Co.) and stored at 4 °C.
lod ina t ion of LDL
LDL was 125I-labeDed by the IC1 method of Karlin et al. (25),
purified over Sephadex G75 columns (20 l cm) and dialysed
against Standard buffer. The trichloroacetic acid precipitates
contained 97 — 99% of the radioactivity. The specific activity
was 200 — 600 counts/min per ng protein.
Acetylation of LDL
LDL apheresis-derived material was acetylated by the method
of Basu et al. (26) and dialysed for 36 h at 4 °C against Standard
buffer. Occasionally turbidity was removed by centrifugation
(12000g, 20 min). Sterile filtration was conducted äs äbove.
Cell transport tests
Human hepatocytes (HepG2, American tissue culture collec-
tion) were used. These cells were routinely screefied for myco-
plasmä infection. Culturing was performed with Eagles mini-
mum essential mediurn containing fetal calf serum, volüme
fraction 0.1, at 37 °C and 5% CO2. For transport experirnents
the cells were trypsinised (0.5 g/l trypsin, 0.5 g/l EDTA) and
transferred into dishes (60 15 mm). On day four, the culture
medium was replaced by lipoprotein-deficient serum, volüme
fraction 0.1, containing medium for 12 to 18 h. The cell protein
concentration at this time was 1—2 mg/dish. Binding, incor^
poration and degradation was determined according to Gold-
Stein & Brown (27).
Murine macrophages (P388, American tissme culture collection)
were cultured in RPMI raedium with addition of non-essential
amino acids and fetal calf serum, volüme fraction 0.1. For
transport tests, the cells were suspended and transferred into
dishes (35 15 mm). When sürviving cells became adherent
(l h), medium was exehanged. LDL uptake was determined by
quantification of intracellülar cholesterol ester using an HPTLC
method (28).
Conjugation of amphiphilic nucleoside derivatives
to LDL
The conjugation was a modification of a method of Havekes
et al. (29). The incubation mixture contained 2.5 g LDL (pro-
tein) per litre final volüme (Standard buffer) and lipoprotein-
deficient serum, volüme fraction 0.25. The nucleoside deriva-
tives were added äs methanolic Solutions (acyl-derivatives: 2 g/1;
trityl-derivatives: 10 g/l) and incübated for 24 h at 37 °C Re-
isolation of LDL was performed by ultracentrifugation after
addition of KBr (125 g/l) at 250 000 g for 22 h. LDL conjugates
float, whereas free amphiphilie nucleoside derivatives are pel-
leted.
Quantif ication of nucleoside binding to LDL
The binding of 3H-labelled nucleosides to LDL was determined
by calculation of specific activity per mg of LDL-protein. An
aliquot (0.5 ml) of LDL nucleoside conjugate or acetyl-LDL
nucleoside conjugate (approx. 500 g protein) was lyophilised
and extracted with l ml methanol for 24 h at room temperature.
After centrifugation, the nucleoside extract was subjected to
HPLC on RP 18. The eluent was acetate buffer (pH 7.2, 50
mmol/l)/methanol in the proportion 15/85, by volüme, for
trityl-azidothyrnidine and 5/95, by volüme for acyl-azido-
thymidine. Detection was at UV 265 nm.
Stability tests
Heparin precipitation
An aliquot (0.5 ml) of LDL-nucleoside conjugate was mixed
with 0.5 ml acetate buffer (pH 4.6; 100 mmol/1 Na-acetate, 200
mmol/I NaCl), incübated with 500 IÜ heparin (25 ) for 15
min at room temperature, then centrifuged (15 min, 12000g).
The supernatant was discarded; the pellet was extracted with
raethanol (1.0 ml). Further processing was peffofmed äs de-
scribed above by HPLC or 3H-labelling. The fraction of hep-
arin-precipitated LDL-nucleoside was calculated frorn the ini-
tial total amount of nucleoside. TJie same procedure was per-
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formed for acetylated LDL using citric acid (pH 2.2; 100
mmol/1) for incubation with heparin.
Dialysis
The LDL conjugates were dialysed at 37 °C against Standard
buffer s indicated. Bo nd nucleoside derivatives were quanti-
fied by 3H-labelling or HPLC.
Equilibrium dialysis
LDL nucleoside conjugate solution (200 μΐ) dialysed against
the same volume of buffer s indicated for 24 h at 37 °C. The
nucleoside redistribution on both sides of the dialysis membrane
was determined by quantification of the bound fraction s
above.
Sephadex gel chromatography
[3H]4'-N-stearoyl-2'-deoxycytidine/LDL conjugate (2.5 mg pro-
tein) was eluted over Sephadex G 75 (30 χ 1.8 cm) with
KH2PO4 (pH 7.4, 50 mmol/1). Fractions of l ml were measured
for cholesterol and 3H activity (nucleoside).
Coincubation test
A mixture of nucleoside-LDL (2 mg cholesterol) and acetyl-
LDL (2 mg cholesterol) was incubated in 3 ml acetate buffer
(100 mmol/1 Na-acetate, 200 mmol/1 NaCl, pH 4.6) at room
temperature for various periods of time (fig. 5). Nucleoside-
LDL-conjugates were precipitated by addition of 25 μΐ heparin
(500 IU), and removed by centrifugation (10 min, 12000g).
Acetylated LDL and acetylated LDL-nucleoside-conjugates re-
main in the supernatant (30).
Covalent ligand coupling
Covalent coupling of thymidine to LDL (from membrane dif-
ferential Filtration apheresis) was achieved by covalent coupling
of 4-nitrophenyl-[3H]thymidine-5'-carbonate (synthcsizcd s de-
scribed in 1. c. (19)) with the apolipoprotein B moiety of LDL
by stepwise addition of 4-nitrophenyl-[3H]thymidine-5'-carbon-
ate (10 mg in 125 μΐ methanol) to borate-buffered (250 mmol/1,
pH 10.0) LDL-solution, with stirring at 4°C. The reaction
solution was centrifuged (15 min, 12000g) to remove insoluble
components and denaturated LDL. The supernatant was pur-
ified by sephadex gel chromatography (Sephadex G 75, 20 χ l
cm). The LDL containing fractions were pooled and analysed
for protein and 3H activity.
Results
At first, we studied the stability of LDL conjugates,
which were prepared by equilibrium techniques, using
conventional stability tests. LDL and acetylated LDL
were conjugated with lipophilised nucleosides (trityl-,
O-stearoyl-azidothymidine, [3H]4'-N-stearoyl-2'-de-
oxycytidine) (tab. l, tab. 2): all tested LDL conjugates
showed > 95% stability in heparin precipitation.
However, trityl-azidothymidine/LDL conjugates re-
vealed an unacceptable instability in Standard dialysis:
dissociation occurred at 37 °C with a half-life of 8 h
(fig. 1). Trityl-azidothymidine was therefore excluded
from further experiments. The acyl-nucleoside deriv-
atives exhibited sufficient stability during Standard
Tab. l. Stability test of LDL conjugates by equilibrium dialysis: 200 μΐ [3H]4'-N-stearoyl-2'-deoxycytidine/LDL-conjugate against
200 μΐ dialysis buffer for 20 h at 37 °C. Drug conjugation was calculated from 3H activity. The activity remaining after











Eagle -h foetal calf 97.8
Bovine serum albumin, 40 g/l serum, 100 ml/l 97.2
LDL, 10 g/l 97.3
Isotonic NaCl 98.6
Eagle-medium 98.7
Eagle + foetal calf 98.5
Bovine serum albumin, 40 g/l serum, 100 ml/l 98.5
LDL, 10 g/l 98.4
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Fig. L Stability of nucleoside/LDL conjugates in Standard di-
alysis. Decrease of conjugated nucleosides äs a function
of time. Dialysis: 34 h at 37 °C against 1000 volumes of
Standard buffer. In the case of [3H]4'-N-stearoyl-2'-de-
oxycytidine/LDL, 81% of 3H activity before dialysis,
and 97% of 3H activity after dialysis was precipitated














Fig. 2. Reisolation of LDL conjugates from lipoprotein-defl·
cient serum-containing incubation medium (ultracentri-
fugation with KBr gradient). 18 fractions (625 each)
from bottom (fraction 1) to top (fraction 18) were
separated and analysed for total cholesterol, protein
(experiment 1) and 3H activity (experiment 3). 95% of
3H activity was found with the cholesterol-containing
LDL fraction; 5% was pelleted with proteins of lipo-
protein deficient serum. A control run without LDL
under identical conditions showed 100% of 3H activity
in the protein pellet.
dialysis (85-94% binding after 34 h at 37 °C). Equi-
librium dialysis against several media (tab. 1) revealed
high stability (> 97% binding after 20 h at 37 °C).
Reisolation of LDL (d = 1.019-1.063 kg/l) after
Substrate conjugation in the presence of lipoprotein-
deficient serum, volume fraction 0.25, by ultracentri-
fugation results in 95% binding of the initial amount
of nucleoside derivative to LDL (fig. 2). Gel chro-
matography of the LDL-nucleoside conjugate dem-
onstrated > 70% binding to the eluted LDL. In sum-
mary, stability tests were satisfactory with acyl-nu-
cleoside/LDL conjugates prepared by equilibrium
methods (tab. 2).
Biological integrity of the LDL conjugates was dem-
onstrated by electrophoretie mobility with SDS-
PAGE and agarose electrophoresis and by celi trans-
port studies with human hepatocytes (Hep G2) and
murine macrophages (P388>. The experiments showed
that conjugation of LDL with amphiphilic nugleoside
derivatives via solution equilibrium neither changed
electrophoretie mobility, nor modified receptor affin-
ity.
Receptor-mediated ligand internalization of LDL-
conjugates was determined by 3H-labellirig of the li-
gand, or 125I-labelling of the LDL particle. Strikingly
different transport behaviour was showü by the 3H-
labelled and 125I4abelled conjugates (fig. 3). [3H]4^N-
stearoyl-2'-deoxycytidine/LDL is ten times more en-
riched than 4/-N-stearoyl-2/-deoxycytidine/[125I]LDL,
when calculated on the basis of a stable LDL conju^·
gate. In contrast, the nucleoside/acetyl-[125I]LDL con-
jugate shows alriiost no internalization. Surprisingly,
[3H]4/-N-stearoyl-2/-deoxycytidine/acetyl-LDL con-
jugates seem to be transported approximately to the
same extent äs [3H]-4/-N-stearoy^2^deoxycytidine/
LDL. The difference between the aeetylated nucleo-
side conjugate and the unacetylated species is 10% in
these experiments. Thus, an unspecific nucleoside in-





Fig. 3. Internalization tests fag/mg cell protein) on Hep G2
hepatocytes with 4'-N-steafoyl-2^deoxycytidine/LDL
or 4/-N-stearoyl-2/-deoxycytidine/acetyl-LDL conju-
gates. Internalization (\ig/mg cell pro.tein) was deter-
mined by [I25I]LDL labelling and by 3H-ligand labelling
of the conjugates. The discrepancy».between both labels
is obvious indicating the non-receptor-mediated uptake
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Fig. 4. Internalizatipn tests on Hep G2 hepatocytes with [3H]4'-
N-stearoyl-2'-deoxycytidine/LDL conjugates in the
presence of an competitive binding compartment. A 20
fold excess of native LDL äs well äs bovine serum




A [3H]4'-N-stearoyl-2'-deoxycytidine + bovine serum
albumin, 40 g/l
In order to analyse these unexpected findings, com-
petition experiments were conducted (flg. 4). Inter-
nalization of [3H]4'-N-stearoyl-2'-'deoxycytidine in he-
patocytes reveals Saturation behaviour. When LDL
(acting äs a competitive receptor binding agent) and
bovine serum albumin (acting äs an unspecific lipo-
philic binding agent) were added to the incubation
media, substantial reduction of [3H]4/-N-stearoyl-2/-
deoxycytidine internalization was observed, i.e. 85%
reduction after adding unconjugated LDL and 70%
reduction after adding albumin.
Ultracentrifugation (KBr gradient) of the incubation
medium used in the competition experiments with
LDL excess showed 99% binding of the [3H]4'-N-
stearoyl-2'-deoxycytidine activity in the LDL fraction;
however, the bovine serum albumin-containing incu-
bation medium showed 95% of the [3H]4'-N-stearoyl-
2'-deoxycytidine activity in the protein pellet.
When macrophages (P388) were loaded with acetyl-
LDL conjugates, the relation between the ligand (3H-
labelled) and cholesteryl ester increment in the cytosol
after incubation did not reflect the ratio of these
components in the LDL conjugate (tab. 3). The in-
crement of intracellular cholesteryl esters due to ace-
tyl-LDL transport is 1.4% of total cholesterol load.
In contrast, [3H]4'-N-stearoyl-2'-deoxycytidine activ-
ity is 6.2% of [3H]4'-N-stearoyl-2'-deoxycytidineload.
Thus, stoichiometric symport has not occurred. On
the other band, loading with unacetylated [3H]4'-N-
stearoyl-2'-deoxycytidine LDL leads to almost the
same intracellular enrichment of activity when com-
pared with the acetyl-LDL conjugate. However, an
increase of intracellular cholesteryl esters was not
found, which indicates that no transport of the una-
cetylated LDL conjugates took place. Furthermore,
in transport experiments with free [3H]4/-N-stearoyl-
2/-deoxycytidine, the presence of bovine serum albu-
min in the incubation medium substantially reduced
[3H]4/-N-stearoyl-2/-deoxycytidine uptake in macro-
phages. Therefore, the presence of an extracellular
lipophilic compartment competed for the ligand with
transmembrane transport.
Tab. 3. Compafison of internalization of [3H]4'-N-stearoyl-2'-deoxycytidine äs free nücleoside derivative, äs LDL conjugate and
äs acetyl-LDL conjugate in the presence and absence of bovine serum albumin, 40 g/l, on P388-macrophages. LDL-
concentratipn: 75 mg/1 medium. LDL coüjugation: 35 $ [3H]4'-N-stearoyl-2'-deoxycytidine / mg acetyl-LDL (total
cholesterol); 30 ug p^'-N-stearoyl^^deoxycytidine / mg LDL (total cholesterol).
The expected coincidence between ligand and LDL-cholesterol internalization was not observed.
Nücleoside
bovine serum albumin, 40 g/l
pHl^-N-stearoyl^^deoxycytidme/LDL -h
bovine serum albumin, 40 g/l
Free [3H]4'-N-stearoyl-2'-deoxycytidine +
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Because the results of the conventional stability tests
did not agree with the results of the cell experiments,
a new method for testing stability, referred to äs the
"coincubation test", was developed (30).
The principle of this test is precipitation of LDL with
heparin at a certain pH after coincubation with acetyl-
LDL, which does not precipitate at this pH. This
precipitation is independent of drug conjugation.
During coincubation of labelled LDL conjugates and
acetyl-LDL (potential conjugate acceptor) a switch of
the ligand can be detected. Because ligand donor
(LDL conjugates) and ligand acceptor (acetyl-LDL)
are equimolar with respect to LDL-cholesterol, the
maximum redistribution of initial ligand radioactivity
is 50%. The redistribution of [3H]4'-N-stearoyl-2'-
deoxycytidine/LDL is accomplished within three min-
utes, indicating instant instability (fig. 5). On the other
hand, of the four tested LDL conjugates, 5'-O-eru-
coyl-azidothymidine/LDL shows a relatively high sta-
bility. [125I]LDL serves äs control and reveals almost
complete stability.
The above results show, that conjugation via solution
equilibrium is not an appropriate method for obtain-
ing stable LDL conjugates. Hence, the method of
covalent ligand coupling was employed using 4-nitro-
phenyl-thymidine-ester (19). Thymidine coupling to'
LDL (19) is limited by protein denaturation, which
occurs at a 4-nitrophenyl-thymidine-ester concentra-







4-Nitrophenyl thymidine ester [g/l]
12
Fig. 6. Efficacy of the covalent coupling reaction: number of
thymidine molecules per LDL pafticle (membrane dif-
ferential filtration LDL-apheresis) äs a function of 4-
nitrophenyl thymidine ester concentration in the reacr
tion medium. Reaction conditions: 250 mmol/1 borate
buffer, pH 10.0, LDL protein coücentration 10 mg/1,
4 °C. Admixture of ^nitrophenyl-thymidine^ester every
5 min. Maximal thymidylation rate equal to 300 thy-
midine molecules per LDL particle is reached at 10 mg
4-nitrophenyl-thymidine-ester (hatched columns). Fur-
ther increase of 4-nitrophenyl-thymidine-ester leads to
denaturation (black columns) of LDL.
60-1
·* 8—5 · i—8 8
Fig. 5. Coincubation test to assess stability of LDL conjugates:
LDL conjugates were coincubated with an equimolar
amount of acetylated (unconjugated) LDL-cholesterol
for a period of time äs indicated. Afterwards the una-
cetylated LDL was selectively precipitated with heparin.
Ligand distribution between supernatant and pellet was
determined; a 50% value is equal to total lability. Note
that DMSO addition during preparation of the LDL
conjugate (4'-N-stearoyl-2'-deoxycytidine/LDL) has no
significant effect on stability.
o 4'-N-stearoyl-2'-deoxycytidine




Fig. 7. Agarose electrophoresis (Beckman Parägon® LiPoGel)
of thymidine-LDL particles with varying thymidine con-
tent.
Lane 1: Native plasma LDL;
lane 2—7: increasiiöig number of thymidine per LDL:
lane 2 = 80, lane 3 = 160, lane 4 = 240, lane 5 = 280,
lane 6 == 290 and lane 7 = 300;
lane 8: acetyl-LDL.
midine is 300 thymidine molecules per molecule apo-
lipoprotein B. Hence, 88% of the 338 lysyl residues
(38) were coupled. The reaction results in the'for-
mation of an ainide bond. This implies that the cou-
pled lysyl residues lose their basic property. Conse-
quently, the surface Charge of LDL-apolipoprotein B
correlates with the thymidylation rate, which is dem*
onstrated by agarose lipoprotein electrophoresis
(fig. 7).
Stability of the thymidine-LDL complex has already
been demonstrated by agarose eleetrophoresis. Fur-
ther evidence of stability is provided by trichloroacetic
acid precipitation: 97—99%* of the initial activity
Eur. J. Clin. Chem, Clin. Biochem. / Vol. 29,1991 / No. 10
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([3H]thymidine) was found in the pellet. The same
amount was found for trichloroacetic acid precipita-
tion of [125I]LDL.
The aim of experiments with hepätocytes (HepG2)
(fig. 8) was to measure the affinity of thymidine-LDL
for the apolipoprotein B receptor. The characteristic
Inhibition of [125I]LDL (substrate) degradation by in-
creasing amounts of unlabelled plasma LDL (inhibi-
tor) in the medium is shown. Replacing the inhibitory
LDL by acetylated LDL does not diminish degrada-
tion of [125I]LDL. If thymidine-LDL is used äs a
competitive inhibitor, a similar effect, i. e. no com-
petitive Inhibition, is seen. Moreover, a small, but
detectable increase of [125I]LDL degradation occurs,
when modified (acetylated or thymidylated) LDL is
used äs a competitive inhibitor. This effect was repro-
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LDL [mg/l]
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Fig. 8. Gell transport experiments on Hep G2 hepätocytes;
competition experiments, Degradation of [?25I]LDL ( §/
mg cell protein, Substrate concentration 10 mg/1 me-
dium) was determined at increasing concentrations of
various, unlabelled LDL preparations. Native LDL
(white columns) acts äs competitive inhibitor; modified
LDL (hatched colümns: acetyl; black: thymidine) does
not decrease Substrate degradation. Incubation condl·
tions: 5% CO2, 37 °C, 4 h.
100
LDL,[mg/l].
Fig. 9. Cell transport experiments on P388 macrophages. Intra-
cellular cholesterylester content äs an indicatpr of LDL
internalization äs a function of the LDL concentration
in the medium. Native LDL (A) does not increase the
intracellular cholesterylester content; acetyl-LDL (·)
and thymidine-LDL (·) increase the intracellular cho-
lesterylester content. Incubation conditions: 5% CO2,
37 °C, 4 h.
Thus, thymidine-LDL is not recognized by the apo-
lipoprotein B receptor pathway, otherwise thymidine-
LDL· would inhibit the degradation of [125I]LDL and
of plasma LDL.
Figure 9 shows the results of transport experiments
with unlabelled LDL particles and macrophages
(P388). Plasma-derived LDL particles were not taken
up by the macrophages, äs indicated by the constancy
of the intracellular cholesteryl ester content. On the
other band, acetyl-LDL and thymidine-LDL were
internalised to the same extent, äs shown by the
increase of intracellular cholesteryl ester.
Discussion
A variety of conjugation methods for different LDL
compartments has been published, employing several
compounds and drugs (8, 9, 31, 36 — 39). However,
nucleosides have not previously been considered äs
ligands. The aim of this study was to prepare nucleo-
side-LDL-conjugates, which can be transported selec-
tively into HIV infected cells via LDL receptor path-
ways.
The results show that amphiphilic nucleoside deriva-
tives conjugated with LDL are not suited for cell-
selective transport via either of the two LDL receptor
pathways, despite the fact that these conjugates show
adequate stability in conventional stability tests.
An explanation of this unexpected finding is provided
by the results of a new type of experiment, which is
referred to äs the "coincubation test". In this test
instability of the LDL conjugates was demonstrated
in the presence of another lipophilic solution com-
partment (acetyl-LDL). Thus, unspecific uptake is
likely to avoid receptor pathways and a direct tränsfer
of the ligand to the cell membrane may occur. Con-
ventional stability tests in pure aqueous media do not
a priori reveal these phenomena, despite the fact that
unstable conjugates, such äs trityl-azidothymidine/
LDL show their character. One may remember, that
in equilibrium dialysis direct contact between both
lipoprotein Solutions is prevented by the dialysis mem-
brane. Thus, only stability in aqueous Solutions and
not in a heterogeneous System can be demonstrated
by the conventional methods.
The results help to Interpret some, äs yet not fully
understood, findings reported in the literature con-
cerning LDL conjugates:
— Iwanik (31) demonstrated, that a substantial
amount of daunomycine (16%) was found in the
plasma membrane in P388 cells, when offered äs
Eur. J. Clin, Chem. Clin. Biochem. / Vol. 29,1991 / No. 10
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LDL conjugate, whereas free daunomycine is
found to 2% in the plasma membrane. This fact
may be explained by direct ligand shift from LDL
to the plasma membrane.
- Rudling's (9) experiments indicated a small specific
uptake of aclacinomycine A in tumour cells (U-
251 MG), when offered äs LDL conjugates.
Hence, a large fraction of the observed total trans-
port must have been unspecific.
- Vitols (8) demonstrated a major unspecific uptake
of anthracycline into white blood cells. In these
experiments LDL conjugates were prepared by
Krieger's reconstitution method. Hence, the as-
sumed stability was probably only partially main-
tained.
— Schöneshöfer (32) demonstrated, that probucol in
plasma is bound to LDL; its half-life is more than
60 days, hence direct transfer to LDL particles
with a half-life of 2 days should have occurred.
Within this frame of reference, the following addi-
tional important fact should be considered. Ever since
the classical work of Goldstein & Brown (27), it is
common practice to demonstrate specificity of LE)L
iiiternalization via the apolipoprotein B receptor path-
way by adding unlabelled LDL äs a competitive in-
hibitor. When this technique is applied to transport
experiments with LDL conjugates, an extensive re-
duction of ligand uptake is observed. The conclusion
however, that this phenomenon is due to displacement
of the LDL conjugate from the receptor, may be
wrong. If, for instance, the addition of albumin causes
a similar reduction, the mechanism must be unspe-
cific. Redistribution of the LDL ligand to now avail-
able lipophilic compartments (LDL-excess, bovine
serum albumin) takes place, äs demonstrated by
working up the incubation media with ultracentrifu-
gation. In conclusion, competition experiments with
LDL äs the competitor are acceptable only when the
LDL conjugate is shown to be stable in the coincu-
bation test.
Since the acyl-nucleoside/LDL conjugates exhibited
instability, covalent coupling of nucleosides to the
protein moiety of the LDL particle was developed.
Thymidine was used äs a representative compound
for dideoxynucleosides. The same coupling reaction
can be applied to any type of nucleoside.
The increased covalent binding of thymidine leads to
the loss of surface cationicity, and thereby to the loss
of apolipoprotein B receptor affinity. Scavenger re-
ceptor affinity is implemented instead. This became
evident in cell transport experiments, in which com-
petitive Inhibition was used äs an indicator of recep-
tor-mediated internalization: the uptake of native 125I-
labelled LDL into HepG2 cells could not be abolished
by thymidine-LDL. On the other hand, in inacro-
phages (PassX thymidine-LÜL was transported in the
same way äs acetyl-LDL, äs indicated by the same
degree of enrichment of intracellular cholesteryl es-
ters.
With respect to the type and degree of revealed surface
modification, agarose electrophoresis and the resülts
of cell transport experiments are in close agreement.
One may remember, that many other modifications
(derivatization with methyl-, glucosyl-, malondialde-
hyde- and hexandione-ligands (33, 18)), which mask
lysyl side chains, lead to the same transport behaviour.
The reported experiments indicate that therapeutic
nucleosides can be selectively targeted to macro-
phages. The enrichment of 10 g cholesteryl ester per
mg cell protein (P388-macrqphages) is equivalent to
the establishment of 600 /1 nucleoside in the
cytosol. Total Inhibition of feverse transcriptase^) in
human macröphages occurs at 10 / azido-
thymidine (34).
However, a prerequisite for phannacological action
of dideoxynucleoside-LDL-cömplexesis the release of
the drug through lysosomal degradation. This remains
to be demonstrated by in vitro reverse transcriptase
Inhibition in infected macröphages.
It is known that macrophages have only a löw poten-
tial for phosphorylating nucleosides, which is a con-
dition for the therapeutic action of nucleoside ana-
logues (35). But it is the ratio of azidothymidine-
triphosphate to thymidine-triphosphate and not the
absolute concentrations of these two compounds that
is responsible for the reverse transcriptase Inhibition
effect (34). Thus, the low thymidine kinase activity
does not necessarily contradict the proposal to treat
macrophages with dideoxynucleosides.
Further experiments are needed to demonstrate
whether, in cell cultures of Hl V4nfected human mac-
rophages, these nucleoside LDL complexes cäri spe-
cifically inhibit HIV replication, A more general con-
sideration of this therapeutic proposal would then be
reasonable.
2) Enzyme: Reverse transcriptase, RNA-directed DNA poly-
meräse (EC 2.7.7.49).
Eur. J. Clin. Chem. Clin. Biochem, / Vol. 29,1991 / No. 10
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